Terms: = Colorectal cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
246 results:
1. Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.
Altves S; Guclu E; Yetisgin E; Bilecen K; Vural H
World J Microbiol Biotechnol; 2024 May; 40(7):204. PubMed ID: 38755413
[TBL] [Abstract] [Full Text] [Related]
2. il-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p.
Gharib E; Rejali L; Piroozkhah M; Zonoobi E; Nasrabadi PN; Arabsorkhi Z; Baghdar K; Shams E; Sadeghi A; Kuppen PJK; Salehi Z; Nazemalhosseini-Mojarad E
J Transl Med; 2024 May; 22(1):439. PubMed ID: 38720389
[TBL] [Abstract] [Full Text] [Related]
3. The combination of il-2 nanoparticles and Palbociclib enhances the anti-tumor immune response for colon cancer therapy.
Wang D; Wang X; Zhang Y; Yu L; An J; Wang X; Huang Y; Han X
Front Immunol; 2024; 15():1309509. PubMed ID: 38352877
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract] [Full Text] [Related]
5. Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases.
Li CMY; Tomita Y; Dhakal B; Tin T; Li R; Wright JA; Vrbanac L; Woods SL; Drew P; Price T; Smith E; Maddern GJ; Fenix K
Cancer Immunol Immunother; 2024 Jan; 73(1):6. PubMed ID: 38231291
[TBL] [Abstract] [Full Text] [Related]
6. Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.
Mahdi HS; Woodall-Jappe M; Singh P; Czuczman MS
Front Immunol; 2023; 14():1268979. PubMed ID: 38022532
[TBL] [Abstract] [Full Text] [Related]
7. Exploring the Therapeutic Potential of Fe
Mahdavi Niyaki Z; Salehzadeh A; Peymani M; Zaefizadeh M
Biol Trace Elem Res; 2024 Jul; 202(7):3073-3085. PubMed ID: 37792268
[TBL] [Abstract] [Full Text] [Related]
8. Reigniting hope in cancer treatment: the promise and pitfalls of il-2 and il-2R targeting strategies.
Muhammad S; Fan T; Hai Y; Gao Y; He J
Mol Cancer; 2023 Jul; 22(1):121. PubMed ID: 37516849
[TBL] [Abstract] [Full Text] [Related]
9. Cytokine concentration in peripheral blood of patients with colorectal cancer.
Li W; Chen F; Gao H; Xu Z; Zhou Y; Wang S; Lv Z; Zhang Y; Xu Z; Huo J; Zhao J; Zong Y; Feng W; Shen X; Wu Z; Lu A
Front Immunol; 2023; 14():1175513. PubMed ID: 37063892
[TBL] [Abstract] [Full Text] [Related]
10. Generation and Functional Characterization of PLAP CAR-T Cells against Cervical cancer Cells.
Yekehfallah V; Pahlavanneshan S; Sayadmanesh A; Momtahan Z; Ma B; Basiri M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139135
[TBL] [Abstract] [Full Text] [Related]
11. Anti-metastatic effects of 1,2,3,4,6-Penta-O-galloyl-β-D-glucose in colorectal cancer: Regulation of cathepsin B-mediated extracellular matrix dynamics and epithelial-to-mesenchymal transition.
Yang H; Yue GG; Leung PC; Wong CK; Zhang YJ; Lau CB
Pharmacol Res; 2022 Oct; 184():106457. PubMed ID: 36116708
[TBL] [Abstract] [Full Text] [Related]
12. pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury.
Chen MC; Lai KS; Chien KL; Teng ST; Lin YR; Chao W; Lee MJ; Wei PL; Huang YH; Kuo HP; Weng CM; Chou CL
Front Immunol; 2022; 13():871828. PubMed ID: 35585988
[TBL] [Abstract] [Full Text] [Related]
13. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
Zhou J; Xu Y; Wang G; Mei T; Yang H; Liu Y
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35552764
[TBL] [Abstract] [Full Text] [Related]
14. Effects of Curcuminoids on Systemic Inflammation and Quality of Life in Patients with colorectal cancer Undergoing Chemotherapy: A Randomized Controlled Trial.
Panahi Y; Saberi-Karimian M; Valizadeh O; Behnam B; Saadat A; Jamialahmadi T; Majeed M; Sahebkar A
Adv Exp Med Biol; 2021; 1328():1-9. PubMed ID: 34981467
[TBL] [Abstract] [Full Text] [Related]
15. Engineering NK-92 Cell by Upregulating CXCR2 and il-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon cancer.
Gao L; Yang L; Zhang S; Ge Z; Su M; Shi Y; Wang X; Huang C
J Interferon Cytokine Res; 2021 Dec; 41(12):450-460. PubMed ID: 34935484
[TBL] [Abstract] [Full Text] [Related]
16. Bioinformatics and
Qin J; Guo C; Yang L; Liang X; Jiao A; Lai KP; Yang B
Bioengineered; 2021 Dec; 12(2):12461-12469. PubMed ID: 34931923
[TBL] [Abstract] [Full Text] [Related]
17. Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects.
Suarez-Carmona M; Williams A; Schreiber J; Hohmann N; Pruefer U; Krauss J; Jäger D; Frömming A; Beyer D; Eulberg D; Jungelius JU; Baumann M; Mangasarian A; Halama N
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607895
[TBL] [Abstract] [Full Text] [Related]
18. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract] [Full Text] [Related]
19. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
20. Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and
Hui Z; Zhang J; Zheng Y; Yang L; Yu W; An Y; Wei F; Ren X
Front Immunol; 2021; 12():619932. PubMed ID: 33868236
[TBL] [Abstract] [Full Text] [Related]
[Next]
